0
Your cart

Your cart is empty

Books > Medicine > General issues > Public health & preventive medicine > Personal & public health > Dietetics & nutrition

Buy Now

Perspectives on Biomarker and Surrogate Endpoint Evaluation - Discussion Forum Summary (Paperback) Loot Price: R1,217
Discovery Miles 12 170
Perspectives on Biomarker and Surrogate Endpoint Evaluation - Discussion Forum Summary (Paperback): Institute of Medicine, Food...

Perspectives on Biomarker and Surrogate Endpoint Evaluation - Discussion Forum Summary (Paperback)

Institute of Medicine, Food and Nutrition Board, Board on Health Sciences Policy, Board on Health Care Services, Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease; Edited by Christine M. Micheel, Erin Balogh, Alison MacK

 (sign in to rate)
Loot Price R1,217 Discovery Miles 12 170 | Repayment Terms: R114 pm x 12*

Bookmark and Share

Expected to ship within 12 - 17 working days

In 2010 the Institute of Medicine (IOM) recommended a framework for the evaluation of biomarkers in the chronic disease setting. Published in the book Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease, the framework is intended to bring consistency and transparency to the previously disparate process of biomarker evaluation. Following the book's release, the IOM convened a 2-day discussion forum in Washington, DC, in order to provide an opportunity for stakeholders to learn about, react to, and discuss the book. Presentations reviewed the authoring committee's work process, recommendations, and provided perspectives on the book from the point of view of participants. Thomas Fleming, professor of biostatistics and statistics at the University of Washington, gave a keynote presentation on the critical issues in the validation of surrogate endpoints, a specific use of a biomarker. The present volume recounts the discussion forum proceedings, focusing in turn on each represented sector. A summary of Dr. Fleming's presentation then sets the committee's recommendations within the context of biomarker utilization. Lastly, this summary examines the main themes raised by stakeholders, and the challenges and opportunities presented to stakeholders by the book's recommendations. Table of Contents Front Matter 1 Introduction 2 Committee Findings and Recommendations 3 FDA Perspectives 4 National Institutes of Health Perspectives 5 Industry Perspectives 6 Public Health, Consumer, and Consulting Organization Perspectives 7 Presentation by Thomas Fleming: Biomarkers and Surrogate Endpoints in Chronic Disease 8 Key Themes, Challenges, and Opportunities 9 Importance of the Biomarker Discussion Forum References Acronyms Glossary Appendix A: Discussion Forum Agenda Appendix B: Summary from the Committee's Report *Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease*

General

Imprint: National Academies Press
Country of origin: United States
Release date: February 2011
First published: 2010
Authors: Institute of Medicine • Food and Nutrition Board • Board on Health Sciences Policy • Board on Health Care Services • Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease
Editors: Christine M. Micheel • Erin Balogh • Alison MacK
Dimensions: 229 x 152 x 13mm (L x W x T)
Format: Paperback
Pages: 140
ISBN-13: 978-0-309-16324-8
Categories: Books > Medicine > General issues > Public health & preventive medicine > Personal & public health > Dietetics & nutrition
LSN: 0-309-16324-2
Barcode: 9780309163248

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!

Partners